Ozempic vs. bariatric surgery in a two-year Lebanon study
The two groups ended at similar BMIs. The surgery group started higher, and the Ozempic group excluded people who stopped early.
Search explainers, questions, and medicine profiles.
The publication’s independent editorial identity, covering weight-management research, treatments and practical strategies. No individual clinician or professional credential is claimed.
How we workMyWeightLab is an independent, evidence-first publication following GLP-1 medicines, obesity-drug research and the practical science of weight management.
This is a publication byline, not a clinician credential. Our articles do not provide diagnosis, prescriptions or individual treatment advice.
We check regulatory documents, trial registries, prescribing information and peer-reviewed research. Trial design, reported results and marketing approval are separate facts. Sponsor announcements are identified as such.
Editorial source review is distinct from independent clinical review. A real reviewer is credited only when their identity and contribution have been verified.
The two groups ended at similar BMIs. The surgery group started higher, and the Ozempic group excluded people who stopped early.
A new review puts flavor in focus. Two small studies and the Wegovy label tell different parts of the story.
A report of depersonalization and derealization raises a question about the medicine that larger studies of depression and suicidality leave open.
The TriNetX analysis concerns adults with artery disease and no diabetes; its findings do not establish equal cardiovascular protection.
The findings concern established MASH with liver scarring, not general eligibility for weight-loss treatment.
The 25.4% headline belongs to a selected group. Delayed responders, missing observations and dose escalation explain why the distinction matters.
A closer look at questionnaire changes, the people included, and why pills and injections cannot be ranked from these data.
The one-year combination results separate joint response from weight loss, with important limits around discontinuation and exploratory testing.
The $3.5 billion project plans injectable production, but approval, launch timing, pharmacy supply and coverage remain separate questions.
The difference between fewer events, an observed mortality signal and proven lifespan extension matters.